| scholarly article | Q13442814 |
| P50 | author | Roland W Sutter | Q90470465 |
| Olen Kew | Q106466698 | ||
| Grace Macklin | Q89542526 | ||
| P2093 | author name string | Stuart Gilmour | |
| Kathleen Dooling | |||
| Yi Liao | |||
| Ondrej Mach | |||
| Marina Takane | |||
| iVDPV Working Group | |||
| P2860 | cites work | VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION * | Q22255613 |
| Circulating vaccine-derived polioviruses: current state of knowledge | Q24655387 | ||
| Update on vaccine-derived polioviruses detected worldwide, April 2011–June 2012 | Q95438579 | ||
| Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range | Q24655520 | ||
| Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model | Q33568783 | ||
| Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient | Q33678253 | ||
| Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. | Q33800863 | ||
| Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication | Q34443617 | ||
| Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative. | Q35757398 | ||
| Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. | Q35779733 | ||
| High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies | Q36362236 | ||
| Vaccine-derived poliovirus from long term excretors and the end game of polio eradication | Q36464879 | ||
| Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995-2014. | Q37288126 | ||
| Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. | Q37542082 | ||
| Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication | Q38323836 | ||
| Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. | Q40590135 | ||
| Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature | Q41514776 | ||
| Possible eradication of wild poliovirus type 3--worldwide, 2012. | Q41958572 | ||
| Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series | Q42183588 | ||
| Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. | Q44401277 | ||
| Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient | Q45222453 | ||
| Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. | Q50183859 | ||
| Consanguinity in Primary Immunodeficiency Disorders; the Report from Iranian Primary Immunodeficiency Registry | Q59636286 | ||
| Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka | Q60634683 | ||
| Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency | Q64045752 | ||
| Apparent global interruption of wild poliovirus type 2 transmission | Q73745317 | ||
| Infectious diseases. Report concludes polio drugs are needed--after disease is eradicated | Q82858519 | ||
| P921 | main subject | World Health Organization | Q7817 |
| Poliovirus | Q70923324 | ||
| P304 | page(s) | 1103 | |
| P577 | publication date | 2017-09-25 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry | |
| P478 | volume | 8 |
| Q64359311 | Accelerated immunodeficiency-associated vaccine derived poliovirus serotype 3 (iVDPV3) sequence evolution rate in a 3-month old boy with X-linked agammaglobulinemia and perinatal HIV exposure |
| Q89285972 | Clearing Vaccine-Derived Poliovirus Infection Following Hematopoietic Stem Cell Transplantation: a Case Report and Review of Literature |
| Q52686332 | New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. |
| Q92756042 | Persistent Infection and Transmission of Senecavirus A from Carrier Sows to Contact Piglets |
| Q58791913 | Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine |
| Q57279875 | Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians' perspectives in the endgame plan for polio eradication |
| Q94597130 | Surveillance Optimization to Detect Poliovirus in the Pre-Eradication Era: a Modelling Study of England and Wales |
| Q91565670 | The case for replacing live oral polio vaccine with inactivated vaccine in the Americas |
| Q58790021 | Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus |
| Q90918713 | Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters |
Search more.